Agios pharmaceuticals Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Agios pharmaceuticals Contact Number

Contact Us Agios The Other Side of Possible

Just Now Agios.com Show details

617-344-0070

[email protected]agios.com; Verification of employment. Fax: 617-344-0070; Email: [email protected]agios.com; For clinical trial data requests. Complete our data sharing request form and send all requests to [email protected]agios.com.

Category: Contact SupportShow more

Agios Pharmaceuticals Crunchbase Company Profile & Funding

1 hours ago Crunchbase.com Show details

(617) 649-8600

Contact Email [email protected]agios.com. Phone Number (617) 649-8600. Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune

Founded: 2008
Founders: Tak Wah Mak, Craig B. Thompson

Category: Contact NumberShow more

Agios The Other Side of Possible

2 hours ago Agios.com Show details

Spirit of Agios. Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiated therapies.

Category: Contact NumberShow more

Agios Pharmaceuticals, Inc. Company Profile Cambridge

9 hours ago Dnb.com Show details

(617) 649-8600

Agios Pharmaceuticals wants to say " adios " to cancer. The biopharmaceutical company is developing metabolic treatments for certain types of cancer and rare genetic diseases. Its lead drug candidates, AG-221 and AG-120, are oral tablets that apply cellular metabolism to treat patients with cancers that harbor certain mutations.

Employees: 382
Phone: (617) 649-8600
Location: 88 Sidney St, Cambridge, 02139-4137, MA

Category: Contact NumberShow more

Agios Pharmaceuticals, Inc. AL, CA, CO, DE, FL, IN, KY

9 hours ago Bizapedia.com Show details

40600 Ann Arbor Road E Ste 201. Plymouth, MI 48170-4675. Registered Agent: The Corporation Company. Filing Date: April 08, 2019. File Number: 802309024. Contact Us About The Company Profile For Agios Pharmaceuticals, Inc.

Category: Contact NumberShow more

Agios Pharmaceuticals Email Format agios.com Emails

4 hours ago Rocketreach.co Show details

Agios Pharmaceuticals Email Format. Agios Pharmaceuticals uses 4 email formats, with first '.' last (ex. [email protected]agios.com) being used 93.9% of the time. Get Verified Emails for Agios Pharmaceuticals Employees. Agios Pharmaceuticals's Email Format. Percentage.

Category: Contact NumberShow more

Agios Pharmaceuticals, Inc. (AGIO) Company Profile

6 hours ago Stockanalysis.com Show details

Company profile for Agios Pharmaceuticals, Inc. (AGIO) with a description, list of executives, contact details and other key facts. Company profile for Agios Pharmaceuticals, Inc. (AGIO) with a description, list of executives, contact details and other key facts. CUSIP Number: 00847X104: ISIN Number: US00847X1046: Employer ID: 26-0662915

Category: Contact NumberShow more

Agios and CStone Pharmaceuticals announce exclusive

1 hours ago Cstonepharma.com Show details

617-649-8299

Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts. Agios Investors Contact: Renee Leck, 617-649-8299

Category: Contact NumberShow more

Agios Clinical Genomics Requisition Form

1 hours ago Perkinelmergenomics.com Show details

the program. Agios receives de-identified patient data from this program, but at no time does Agios receive patient identifiable information. Agios receives contact information for healthcare providers who use this program. Genetic testing is available in the U.S. and Puerto Rico only. Healthcare providers who use this program have no obligation

Category: Contact NumberShow more

Agios Pharmaceuticals, Inc. (AGIO) Company Profile & Facts

4 hours ago Finance.yahoo.com Show details

See the company profile for Agios Pharmaceuticals, Inc. (AGIO) including business summary, industry/sector information, number of employees, business summary, corporate governance, key …

Category: Contact NumberShow more

Agios Pharmaceuticals Corporate Headquarters, Office

8 hours ago Craft.co Show details

Agios Pharmaceuticals is headquartered in Cambridge, MA and has 1 office location across 1 country. View Company. Filter locations by country.

Category: Contact NumberShow more

Our Research Platform Agios The Other Side of Possible

3 hours ago Agios.com Show details

Our Research Platform. At our core, we are a science-driven research organization. We have built a discovery platform upon our expertise in the field of cellular metabolism, specifically in genetically defined diseases. We take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel

Category: Contact NumberShow more

Alaven Pharmaceutical Llc in Marietta Location, Contact

2 hours ago Npino.com Show details

678-589-7000

Alaven Pharmaceutical Llc (ALAVEN PHARMACEUTICAL LLC) is a Durable Medical Equipment & Medical Supplies Supplier - Customized Equipment in Marietta, Georgia.The NPI Number for Alaven Pharmaceutical Llc is 1164737508. The current location address for Alaven Pharmaceutical Llc is 200 Cobb Pkwy N, Suite 428, Marietta, Georgia and the contact number is 678-589-7000 and fax …

Category: Contact SupportShow more

Agios Pharmaceuticals Company Profile Office Locations

8 hours ago Craft.co Show details

Agios Pharmaceuticals has 536 employees at their 1 location and $203.2 M in annual revenue in FY 2020. See insights on Agios Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Category: Contact NumberShow more

Leadership Agios The Other Side of Possible

9 hours ago Agios.com Show details

Agios Pharmaceuticals Dr. Fouse has served as a member of our board of directors since December 2017 and became chief executive officer of Agios in February 2019. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017.

Category: Contact NumberShow more

Our History Agios The Other Side of Possible

Just Now Agios.com Show details

2009. Labs opened in January 2009. Agios groundbreaking research establishes for the first time that the mutated metabolic gene IDH1 has novel enzyme activity consistent with an oncogene and publishes the article in Nature. Continued to build the company’s research platform.

Category: Contact NumberShow more

Agios Pharmaceuticals Wikipedia

1 hours ago En.wikipedia.org Show details

Agios Pharmaceuticals. Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 (or 2007) by Lewis

Category: Contact NumberShow more

Agios Pharmaceuticals Number of Employees 20122021 AGIO

8 hours ago Macrotrends.net Show details

Agios Pharmaceuticals number of employees from 2012 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

Category: Contact NumberShow more

Agios Announces Updated Data from Phase 1 Study of

6 hours ago Investor.agios.com Show details

CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported updated data from a Phase 1 trial of mitapivat, the company’s first-in-class pyruvate kinase R (PKR) activator, in patients with sickle cell disease.

Category: Contact NumberShow more

Agios Grants Management System Visiontracker reuenty Ased

9 hours ago Agios.envisionpharma.com Show details

Agios Grants Management System Visiontracker reuenty Ased uestions As e0 – Click Complete Request under the column What would you like to do? to open the application. – Applications that require you to provide information or an update will appear in your Task List. Click the Tracking Number or the link under the column What would

Category: Contact NumberShow more

Agios Reports Business Highlights and Second Quarter 2019

9 hours ago Investor.agios.com Show details

CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported business highlights and financial results for the second quarter ended June 30, 2019.

Category: Contact NumberShow more

AGIOS PHARMACEUTICALS, INC. : Shareholders Board Members

5 hours ago Marketscreener.com Show details

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias.

Category: Contact NumberShow more

Lewis C. Cantley, Founder at Agios Pharmaceuticals, Inc

2 hours ago Relationshipscience.com Show details

Petra Pharma Corp. operates as a drug development company that develops novel small molecules for the treatment of cancer and metabolic diseases. The company was founded by Lewis Clayton Cantley and Nathanael S. Gray in 2016 and is headquartered in New York, NY. Details Hidden. Agios Pharmaceuticals, Inc.

Category: Contact NumberShow more

Agios Announces Phase 3 ACTIVATET Trial of Mitapivat

1 hours ago Investor.agios.com Show details

CAMBRIDGE, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the global, open-label Phase 3 ACTIVATE-T trial of mitapivat in regularly transfused adults with PK deficiency demonstrated a

Category: Contact NumberShow more

Independent Medical Education Envision Pharma Group

5 hours ago Agios.envisionpharma.com Show details

Independent Medical Education IME ser Guide 14eb2019 When the Activity and Outcomes reconciliations are complete, the Submission Requirements bar will indicate 100% and the application can be submitted for review. Click Submit, and then OK to close the Request Resubmitted window. 10.

Category: Contact NumberShow more

Agios Reports Business Highlights and First Quarter 2021

8 hours ago Investor.agios.com Show details

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported business highlights and financial results for the first quarter ended March 31, 2021.

Category: Contact NumberShow more

AGIOS PHARMACEUTICALS, INC. : AGIO Stock Price

7 hours ago Marketscreener.com Show details

562. Free-Float. 80,9%. More Financials. Company. Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias.

Category: Contact NumberShow more

Agios Launches myAgios® Patient Support Services for

4 hours ago Finance.yahoo.com Show details

CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and …

Category: Support NumberShow more

John Maraganore Member of the Board of Directors @ Agios

9 hours ago Crunchbase.com Show details

Number of Current Board & Advisor Roles 3 Number of Past Board & Advisor Roles 2 John Maraganore holds 3 board and advisor roles including Member of the Board of Directors at Agios Pharmaceuticals , Member of the Board of Directors at Alnylam Pharmaceuticals , and Member of the Board of Directors at CytomX Therapeutics .

Category: Contact NumberShow more

Agios Pharmaceuticals Funding, Financials, Valuation

Just Now Crunchbase.com Show details

Agios Pharmaceuticals has raised a total of $119.8M in funding over 4 rounds. Their latest funding was raised on Nov 17, 2011 from a Series C round. Agios Pharmaceuticals is registered under the ticker NASDAQ:AGIO . Their stock opened with $18.00 in its Aug 2, 2013 IPO. Agios Pharmaceuticals is funded by 4 investors.

Category: Contact NumberShow more

Contact Alnylam® Pharmaceuticals

5 hours ago Alnylam.com Show details

617.551.8200

ALNYLAM PHARMACEUTICALS, INC – CORPORATE HEADQUARTERS. 675 West Kendall St Cambridge, MA 02142 USA Tel: 617.551.8200 Fax: 617.551.8101

Category: Contact SupportShow more

Servier Completes Acquisition of Agios Pharmaceuticals

3 hours ago Servier.us Show details

PARIS and BOSTON, April 1, 2021 /PRNewswire/ -- Servier, a global pharmaceutical company, today announced that it has successfully completed its acquisition of Agios Pharmaceuticals' commercial, clinical, and research-stage oncology portfolio for up to $2 billion plus royalties.

Category: Contact NumberShow more

Marc Hyer Disease Biology Expert, Pharmacology and

5 hours ago Linkedin.com Show details

Agios Pharmaceuticals Jul 2017 - Apr 2021 3 • Identified a “bystander effect” whereby the number of apoptotic cells was greater than the number of cells transduced with a Fas Ligand

Title: Associate Director at Servier …
Location: Greater Boston
Connections: 404

Category: Contact NumberShow more

Visiontracker Envision Pharma Group

2 hours ago Agios.envisionpharma.com Show details

Welcome to the Agios Grants Management System. For Agios IME Open Request for Applications: PKD Disease, please see Independent Medical Education page. Please click each program below for additional information and guidelines.

Category: Contact NumberShow more

Document SEC

3 hours ago Sec.gov Show details

I am pleased to extend to you a contingent offer for the position of Chief Scientific Officer at Agios Pharmaceuticals, Inc. (the “Company”), reporting to me with a start date of January 6, 2020. You will receive a semi-monthly salary of $20,833.34 which is equivalent to $500,000.16 annually.

Category: Contact NumberShow more

Agios Launches Anemia ID, a NoCost Genetic Testing

3 hours ago Finance.yahoo.com Show details

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today

Category: Contact NumberShow more

Agios Pharmaceuticals : Launches my Patient Support

1 hours ago Marketscreener.com Show details

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced the launch of myAgios patient support services for people living with pyruvate kinase (PK) deficiency and their caregivers. After enrolling in the program, patients and caregivers will be …

Category: Support NumberShow more

Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug

9 hours ago Finance.yahoo.com Show details

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency. Contact Us . …

Category: Contact NumberShow more

Agios Announces FDA Orphan Drug Designation Granted to

7 hours ago Finance.yahoo.com Show details

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today

Category: Contact NumberShow more

Contact Gyroscope

6 hours ago Gyroscopetx.com Show details

Please contact us. Please note: If you are a patient, family member or healthcare professional please use the contact form specific for Patients and Families.. For all other enquiries simply complete the form with as much information as possible. Please do not include any health information via this general contact form.. We look forward to hearing from you.

Category: Contact SupportShow more

Figurative Trademark of Agios Pharmaceuticals, Inc

5 hours ago Trademarkelite.com Show details

By Agios Pharmaceuticals, Inc. The Figurative trademark was assigned an Application Number # 018494342 – by the European Union Intellectual Property Office (EUIPO). Trademark Application Number is a unique ID to identify the Figurative mark in EUIPO.

Category: Contact NumberShow more

About PK Deficiency For HCPs

9 hours ago Knowpkdeficiency.com Show details

Data on file. Agios Pharmaceuticals, Inc. Cambridge, MA. 10. Carey PJ, Chandler J, Hendrick A, et al; Northern Region Haematologists Group. Prevalence of pyruvate kinase deficiency in a northern European population in the north of England. Blood. 2000;96(12):4005-4006. 11.

Category: Contact NumberShow more

Agios Pharmaceuticals : Reports Business Highlights and

2 hours ago Marketscreener.com Show details

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported business highlights and financial results for the first quarter ended March 31, 2021.

Category: Contact NumberShow more

Robert Nelsen CoFounder & Managing Director @ ARCH

9 hours ago Crunchbase.com Show details

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion.

Category: Contact NumberShow more

Perry Karsen Member of the Board of Directors @ Sonoma

8 hours ago Crunchbase.com Show details

Perry Karsen, Chairman of Pliant’s Board of Directors, served most recently as the Chief Executive Officer of Celgene Cellular Therapeutics from May 2013 until his retirement at the end of 2015. While at Celgene Cellular Therapeutics, Karsen served in a variety of executive roles, including Executive Vice President and Chief Operations Officer,

Category: Contact NumberShow more

Agios Pharmaceuticals Inc. (AGIO) Volatility Hits 3.89%

7 hours ago Stocksregister.com Show details

Having a second look at Agios Pharmaceuticals Inc. (NASDAQ:AGIO) provides that stock’s average daily trading volume for 3 months was 567.87K. Number of outstanding shares of the stock stood at 61.07 million. >> 7 Top Picks for the Post-Pandemic Economy

Category: Contact NumberShow more

$AGIO: Investors will love the forecast for Agios

9 hours ago Wallstreetfacts.com Show details

The 52-week high for Agios Pharmaceuticals Inc is $62.16 and the low is $32.47. We will be moving onto the number of outstanding shares. One is that you can use shares outstanding to calculate the market capitalization, the total value, of a corporation.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is agios pharmaceuticals inc?

Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway.

Where do i go to get an agios user id?

If you are a first time user, please click the link under "Need a User ID" on the left side of the screen to begin the registration process and obtain a User ID. Agios supports grants for independent medical education to advance knowledge in medicine and healthcare by improving awareness and understanding in the medical community.

Who is the chief commercial officer of agios?

Earlier, she served in several human resources positions for The Gillette Company. Ms. McLaughlin earned a Bachelors degree in human resources management from Boston College, Carroll School of Management and a Masters degree from INSEAD. Mr. Miles joined Agios in 2015 and currently serves as chief commercial officer.

How can i make a donation to agios?

Please contact [email protected] Agios is passionately committed to improving the lives of patients and families affected by cancer and rare generic diseases. Through charitable donations to healthcare-related non-profit organization, we support:

Brand New Updated

Popular Brands

Amazon
Abbvie
Aia
Asml
Amgen
Att
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes